02
2022-01
Suzhou, January 2, 2022 - 真人直营投注网站, a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first dosing in its phase III clinical trial of KX-826 in China for the treatment of male androgenetic alopecia (AGA) patients on December 31, 2021.
27
2021-12
Suzhou, December 27, 2021 — 真人直营投注网站 (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today provided an update on its multi-regional study of proxalutamide for the treatment of COVID 19 infection (NCT04870606).
24
2021-11
Suzhou, November 24, 2021 - 真人直营投注网站 (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the IND application for the pivotal study (phase III stage) of pyrilutamide (KX-826), a potential first-in-class drug developed by Kintor Pharma, for the treatment of male androgenetic alopecia (“AGA”) patients was cleared by the National Medical Products Administration (“NMPA”). KX-826 is the first androgen receptor (AR) antagonist which has entered the phase III clinical trial for AGA treatment in China and global.
12
2021-11
Suzhou, November 12, 2021 - 真人直营投注网站 (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the company has dosed the first patient in its phase II clinical trial of pyrilutamide ("KX-826") in China for the treatment of androgenetic alopecia (AGA) female patients.
09
2021-11
Indonesian Ambassador to China and the Delegation Visited Kintor
In the afternoon of November 8, 2021, Indonesian Ambassador to China, H.E. Djauhari Oratmangun, Indonesian Consul General in Shanghai, Mr. Deny Wachyudi Kurnia, and the Chairman of the Indonesia Chamber of Commercein China, Mr. Liky Sutikno, visited Kintor Pharma for in-depth understanding of the company. The delegation met with founder, Chairman and CEO, Dr. Youzhi Tong and Kintor Pharma’s executives.
03
2021-11
Suzhou, November 3, 2021 — 真人直营投注网站 (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company has enrolled and dosed its first patient with advanced or refractory solid tumors in a clinical trial of ALK-1 antibody (GT90001) in combination with KN046 on November 2 in Taiwan, China.
Find Us
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn